FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054717635> ?p ?o ?g. }

• W2054717635 endingPage "145" @default.
• W2054717635 startingPage "137" @default.
• W2054717635 abstract "Tofacitinib (CP-690,550) is a novel Janus kinase inhibitor in development as an oral formulation for the treatment of several inflammatory diseases including psoriasis.This phase 2a study aimed to assess the efficacy, systemic safety, local tolerability and systemic pharmacokinetics of topical tofacitinib in mild-to-moderate plaque psoriasis.Two tofacitinib ointment formulations were evaluated in this multicentre, double-blind, vehicle-controlled trial (NCT01246583). Seventy-one patients were randomized 2 : 1 : 2 : 1 to 2% tofacitinib ointment 1, vehicle 1, 2% tofacitinib ointment 2 and vehicle 2, each administered twice daily for 4 weeks to a single fixed 300 cm(2) treatment area containing a target plaque with or without one or more nontarget plaques and normal skin.The primary endpoint of percentage change from baseline in the Target Plaque Severity Score at week 4 demonstrated statistically significant improvement for ointment 1 [least squares mean (LSM) -54.4%] vs. vehicle 1 (LSM -41.5%), but not ointment 2 (LSM -24.2%) vs. vehicle 2 (LSM -17.2%). Secondary endpoints (target plaque area and Itch Severity Item) improved similarly for tofacitinib ointment vs. corresponding vehicle. Adverse event (AE) occurrence was similar across treatment groups. All AEs were mild or moderate and none were serious or led to subject discontinuation. One application-site AE (erythema) was reported. Tofacitinib mean systemic exposure was minimal and was greater for ointment 1 than for ointment 2.Tofacitinib ointment 1 was well tolerated and efficacious compared with vehicle for the treatment of plaque psoriasis. Further study of topical tofacitinib for psoriasis treatment is warranted." @default.
• W2054717635 created "2016-06-24" @default.
• W2054717635 creator A5007839850 @default.
• W2054717635 creator A5008286260 @default.
• W2054717635 creator A5012671195 @default.
• W2054717635 creator A5020758385 @default.
• W2054717635 creator A5029971595 @default.
• W2054717635 creator A5077567728 @default.
• W2054717635 creator A5086316777 @default.
• W2054717635 date "2013-07-01" @default.
• W2054717635 modified "2023-10-08" @default.
• W2054717635 title "A randomized phase 2a efficacy and safety trial of the topical <scp>J</scp> anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis" @default.
• W2054717635 cites W1990105300 @default.
• W2054717635 cites W1991688187 @default.
• W2054717635 cites W1993625817 @default.
• W2054717635 cites W2005109912 @default.
• W2054717635 cites W2035777672 @default.
• W2054717635 cites W2038992287 @default.
• W2054717635 cites W2045163297 @default.
• W2054717635 cites W2048964610 @default.
• W2054717635 cites W2057259178 @default.
• W2054717635 cites W2069302785 @default.
• W2054717635 cites W2074435026 @default.
• W2054717635 cites W2086831075 @default.
• W2054717635 cites W2098223746 @default.
• W2054717635 cites W2116526448 @default.
• W2054717635 cites W2121219094 @default.
• W2054717635 cites W2149189075 @default.
• W2054717635 cites W2150792818 @default.
• W2054717635 cites W2152532651 @default.
• W2054717635 cites W2153414586 @default.
• W2054717635 cites W2165302503 @default.
• W2054717635 cites W2167305078 @default.
• W2054717635 cites W2561759163 @default.
• W2054717635 doi "https://doi.org/10.1111/bjd.12266" @default.
• W2054717635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3761190" @default.
• W2054717635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23387374" @default.
• W2054717635 hasPublicationYear "2013" @default.
• W2054717635 type Work @default.
• W2054717635 sameAs 2054717635 @default.
• W2054717635 citedByCount "179" @default.
• W2054717635 countsByYear W20547176352012 @default.
• W2054717635 countsByYear W20547176352013 @default.
• W2054717635 countsByYear W20547176352014 @default.
• W2054717635 countsByYear W20547176352015 @default.
• W2054717635 countsByYear W20547176352016 @default.
• W2054717635 countsByYear W20547176352017 @default.
• W2054717635 countsByYear W20547176352018 @default.
• W2054717635 countsByYear W20547176352019 @default.
• W2054717635 countsByYear W20547176352020 @default.
• W2054717635 countsByYear W20547176352021 @default.
• W2054717635 countsByYear W20547176352022 @default.
• W2054717635 countsByYear W20547176352023 @default.
• W2054717635 crossrefType "journal-article" @default.
• W2054717635 hasAuthorship W2054717635A5007839850 @default.
• W2054717635 hasAuthorship W2054717635A5008286260 @default.
• W2054717635 hasAuthorship W2054717635A5012671195 @default.
• W2054717635 hasAuthorship W2054717635A5020758385 @default.
• W2054717635 hasAuthorship W2054717635A5029971595 @default.
• W2054717635 hasAuthorship W2054717635A5077567728 @default.
• W2054717635 hasAuthorship W2054717635A5086316777 @default.
• W2054717635 hasBestOaLocation W20547176352 @default.
• W2054717635 hasConcept C126322002 @default.
• W2054717635 hasConcept C16005928 @default.
• W2054717635 hasConcept C168563851 @default.
• W2054717635 hasConcept C197934379 @default.
• W2054717635 hasConcept C203092338 @default.
• W2054717635 hasConcept C2776233030 @default.
• W2054717635 hasConcept C2777575956 @default.
• W2054717635 hasConcept C2778375690 @default.
• W2054717635 hasConcept C2778715236 @default.
• W2054717635 hasConcept C2778886723 @default.
• W2054717635 hasConcept C2779121184 @default.
• W2054717635 hasConcept C2780564577 @default.
• W2054717635 hasConcept C3020604521 @default.
• W2054717635 hasConcept C71924100 @default.
• W2054717635 hasConcept C90924648 @default.
• W2054717635 hasConcept C98274493 @default.
• W2054717635 hasConceptScore W2054717635C126322002 @default.
• W2054717635 hasConceptScore W2054717635C16005928 @default.
• W2054717635 hasConceptScore W2054717635C168563851 @default.
• W2054717635 hasConceptScore W2054717635C197934379 @default.
• W2054717635 hasConceptScore W2054717635C203092338 @default.
• W2054717635 hasConceptScore W2054717635C2776233030 @default.
• W2054717635 hasConceptScore W2054717635C2777575956 @default.
• W2054717635 hasConceptScore W2054717635C2778375690 @default.
• W2054717635 hasConceptScore W2054717635C2778715236 @default.
• W2054717635 hasConceptScore W2054717635C2778886723 @default.
• W2054717635 hasConceptScore W2054717635C2779121184 @default.
• W2054717635 hasConceptScore W2054717635C2780564577 @default.
• W2054717635 hasConceptScore W2054717635C3020604521 @default.
• W2054717635 hasConceptScore W2054717635C71924100 @default.
• W2054717635 hasConceptScore W2054717635C90924648 @default.
• W2054717635 hasConceptScore W2054717635C98274493 @default.
• W2054717635 hasIssue "1" @default.
• W2054717635 hasLocation W20547176351 @default.
• W2054717635 hasLocation W20547176352 @default.
• W2054717635 hasLocation W20547176353 @default.

• next